The Beauty Health Company (NASDAQ: SKIN) reported Q2 EPS of ($0.10), $0.08 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $90.6 million versus the consensus estimate of $98.75 million.

GUIDANCE:

The Beauty Health Company sees Q3 2024 revenue of $70-80 million, versus the consensus of $100.4 million.

The Beauty Health Company sees FY2024 revenue of $325-345 million, versus the consensus of $391.8 million.

For earnings history and earnings-related data on The Beauty Health Company (SKIN) click here.